Earlier Use of Exelixis/Ipsen's Cabozantinib Hits Hurdle In Liver Cancer
Top-line COSMIC-312 Results
Exelixis/Ipsen’s novel combination of cabozantinib and atezolizumab has produced mixed top-line results from the Phase III COSMIC-312 study, and although the companies are pressing ahead with further analyses, the doublet may struggle to compete in the first-line advanced liver cancer setting.
